Vir Biotechnology To Reveal Expanded Phase 2 SOLSTICE Results for Elebsiran And Tobevibart In Hepatitis Delta at AASLD’s The Liver Meeting 2026

Vir Biotechnology, Inc. (NASDAQ: VIR) will present expanded results from its Phase 2 SOLSTICE trial, which evaluates the combination of elebsiran and tobevibart for chronic hepatitis delta. This presentation is scheduled for the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2026, taking place in Denver, CO from November 5-9, 2026.